AE Wealth Management Boosts Bristol Myers Squibb Stake

Institutional investor increases position in pharmaceutical giant by 31.6%

Apr. 18, 2026 at 7:06am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, industrial machinery and mechanical components, representing the behind-the-scenes financial infrastructure supporting the pharmaceutical industry.Institutional investors continue to back Bristol Myers Squibb's pharmaceutical operations, as evidenced by AE Wealth Management's increased stake in the company.Princeton Today

AE Wealth Management LLC, an investment management firm, has increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 31.6% in the fourth quarter, according to a recent SEC filing. The firm now owns 400,952 shares of the biopharmaceutical company's stock, valued at $21.63 million.

Why it matters

This investment move by AE Wealth Management reflects ongoing institutional confidence in Bristol Myers Squibb's growth prospects, particularly in its core oncology and immunology drug portfolios. As a major player in the pharmaceutical industry, Bristol Myers Squibb's performance is closely watched by investors.

The details

According to the SEC filing, AE Wealth Management added 96,299 shares of Bristol Myers Squibb to its portfolio during the fourth quarter. This increased the firm's total position in the company to 400,952 shares. The investment is part of AE Wealth Management's broader strategy of allocating capital to large-cap pharmaceutical stocks with promising drug pipelines and market share.

  • The SEC filing was made on April 18, 2026, covering the fourth quarter of 2025.
  • AE Wealth Management increased its Bristol Myers Squibb stake during the fourth quarter of 2025.

The players

AE Wealth Management LLC

An investment management firm that has increased its stake in Bristol Myers Squibb Company.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We remain confident in Bristol Myers Squibb's ability to drive long-term growth through its innovative drug pipeline and market leadership in key therapeutic areas.”

— AE Wealth Management, Investment Manager

What’s next

Investors will be closely watching Bristol Myers Squibb's upcoming earnings report and pipeline updates for signs of continued momentum.

The takeaway

This investment by AE Wealth Management underscores the ongoing institutional confidence in Bristol Myers Squibb's position as a leading biopharmaceutical company with a strong drug portfolio and growth prospects.